An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio to Participate in the Stifel 2021 Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Iveric Bio, trading under the symbol ISEE, announced that CEO Glenn P. Sblendorio and President Pravin U. Dugel, M.D., will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. Investors can access the audio webcast on the Iveric Bio website's Investor/Events & Presentations section, with an archived replay available for 30 days following the event. Iveric Bio focuses on developing treatments for retinal diseases, including age-related macular degeneration.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:40 a.m. ET.
An audio webcast of the fireside chat can be accessed on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.
